Tardive dyskinesia
| Tardive dyskinesia | |
| ICD-10 | G24.0 |
|---|---|
| ICD-9 | 333.85 |
| OMIM | 272620 |
| DiseasesDB | 12909 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Tardive dyskinesia (TD) is a persistent, potentially irreversible hyperkinetic movement disorder caused by chronic exposure to dopamine receptor–blocking agents (DRBAs) — chiefly antipsychotics, but also antiemetics such as metoclopramide and prochlorperazine.[1][2] It is characterized by involuntary, repetitive movements most often affecting the orobuccolingual region (tongue protrusion, lip smacking, chewing, grimacing), and frequently the limbs and trunk.[3][4][5] Diagnosis is clinical, based on characteristic movements, a compatible DRBA exposure history, and persistence of movements for at least 4 weeks. The Abnormal Involuntary Movement Scale (AIMS) — a 12-item scale scored 0–40 — is the standard screening and monitoring instrument, with a baseline examination at treatment initiation and periodic reassessment thereafter.[6][7] The VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo) are the only FDA-approved treatments for TD and are the evidence-based first-line agents (AAN Level A), acting by depleting presynaptic dopamine.[8][9][10] Anticholinergics are ineffective and may worsen TD, a critical distinction from drug-induced parkinsonism.[3][11][12]
Definition and diagnostic criteria
Per the American Psychiatric Association's DSM-5-TR, the essential features are abnormal, involuntary movements of the tongue, jaw, trunk, or extremities developing in association with DRBA use.[3] Diagnostic requirements:
- Movement character: Choreiform (rapid, jerky, nonrepetitive), athetoid (slow, sinuous), or semirhythmic stereotypies — distinct from the rhythmic 3–6 Hz tremor of medication-induced parkinsonism.[3][13]
- Duration of movements: Present for at least 4 weeks.[3]
- Exposure threshold: History of DRBA use for at least 3 months, or 1 month in patients ≥60 years.[3]
- Temporal window: Onset during exposure or within 4 weeks of withdrawal from an oral agent (8 weeks for a long-acting injectable).[3]
Distribution: Orofacial movements are the most common manifestation; roughly half of patients have limb involvement and up to one-quarter have axial (neck, shoulder, trunk) dyskinesia. Pharyngeal, diaphragmatic, or abdominal involvement is uncommon.[3]
Pathophysiology
The exact mechanism is unknown. The leading hypothesis is postsynaptic D2 receptor upregulation and supersensitivity following chronic dopamine blockade; oxidative stress from free-radical neurotoxicity and synaptic/GABAergic dysfunction are also implicated.[14][4] Mechanistically, TD is a hyperkinetic disorder reflecting relative dopamine excess and acetylcholine deficiency — the pharmacologic opposite of drug-induced parkinsonism — which explains why anticholinergics do not help and may aggravate TD, and why presynaptic dopamine depletion via VMAT2 inhibition is therapeutic.[12]
Causes and offending agents
TD results from cumulative DRBA exposure.[3] Culprits include:
- First-generation antipsychotics (FGAs): Haloperidol, fluphenazine, perphenazine, chlorpromazine, thioridazine, trifluoperazine — highest liability.[4][2]
- Second-generation antipsychotics (SGAs): Risperidone, olanzapine, quetiapine, and others — lower but non-negligible risk; clozapine carries the lowest risk and quetiapine/clozapine are preferred when TD emerges.[4][5]
- Non-antipsychotic DRBAs: Metoclopramide, prochlorperazine.[1][15]
Epidemiology and risk factors
Pooled prevalence is approximately 21% with SGAs and 30% with FGAs; among patients exposed exclusively to SGAs and never to FGAs, prevalence falls to about 7%.[16] Annual incidence is approximately 6.5% for FGAs versus 2.6% for SGAs.[16] Trial data report annualized incidence of 3.9% (SGA) versus 5.5% (FGA) and prevalence of 13% (SGA) versus 32% (FGA).[4] Because SGAs are far more widely prescribed and the population is aging, the absolute number of cases is likely rising.[16]
The most consistent risk factors are older age and greater cumulative DRBA exposure.[3] Additional factors: postmenopausal/female sex, early acute extrapyramidal symptoms/drug-induced parkinsonism, mood disorders (especially major depression), neurologic conditions, and alcohol use disorder.[3] Younger patients (<60 years) are about three times more likely to remit spontaneously.[14]
Clinical features, natural history, and complications
Onset is insidious and often mild, escaping notice initially.[3] The course fluctuates and, once established, TD is frequently persistent — remission is uncommon, and untreated TD has a low remission rate even after the offending drug is stopped.[12][16] Continued DRBA use in older patients increases the likelihood of more severe or generalized disease.[3] Complications of severe TD include oral/tongue/cheek ulceration, tooth loss, macroglossia, dysphagia, gait and respiratory impairment, muffled speech, weight loss, plus depression, social avoidance, and suicidal ideation.[3]
Differential diagnosis
TD is a clinical diagnosis; laboratory and imaging studies serve only to exclude mimics.[3] The single most important distinction is from drug-induced parkinsonism (DIP): anticholinergics treat DIP but worsen TD, while VMAT2 inhibitors treat TD but worsen DIP.[3][7]
| Disease | Diagnosis | Treatment | ||
|---|---|---|---|---|
| Symptoms | Signs | Laboratory / Diagnostic Findings | ||
| Tardive dyskinesia[3][17] |
|
|
|
|
| Drug-induced parkinsonism[3][12] |
|
|
|
|
| Acute dystonia[3] |
|
|
|
|
| Acute/subacute akathisia[3][12] |
|
|
|
|
| Tardive dystonia[16][18] |
|
|
|
|
| Huntington disease[3] |
|
|
|
|
| Wilson disease[3] |
|
|
|
|
| Sydenham chorea / SLE chorea[3] |
|
|
|
|
| Thyrotoxicosis[3] |
|
|
|
|
| Spontaneous / edentulous dyskinesia[3] |
|
|
|
|
| Withdrawal-emergent dyskinesia[3][16] |
|
|
|
|
Screening and monitoring
Systematic surveillance of DRBA-treated patients with the Abnormal Involuntary Movement Scale (AIMS) is recommended, with a baseline assessment before or at treatment initiation and periodic reassessment thereafter, and again when starting TD-directed therapy to track response.[7][17] Early diagnosis matters because the risk of permanence increases over time.[7]
Management
Primary prevention is foundational: use the lowest effective DRBA dose for the shortest necessary duration, prefer SGAs over FGAs, avoid unnecessary long-term metoclopramide/prochlorperazine, avoid parkinsonian adverse effects and akathisia, and obtain informed consent.[17][15]
First-line pharmacotherapy (VMAT2 inhibitors)
- Dosing: Valbenazine is initiated at 40 mg once daily and increased to 80 mg once daily after 1 week (40 mg may be continued in some patients).[8] Deutetrabenazine (Austedo) is started at 6 mg twice daily and titrated weekly by 6 mg/day to a maximum of 48 mg/day (maximum 36 mg/day in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors); Austedo XR is dosed once daily.
- Phase 3 trials showed clinically meaningful AIMS reductions versus placebo (valbenazine 80 mg −3.2, 40 mg −1.9 vs −0.1; deutetrabenazine 36 mg −3.3, 24 mg −3.2 vs −1.4). A 2025 network meta-analysis confirmed valbenazine and deutetrabenazine as the only evidence-based first-line agents when higher-quality trials are considered; the VA/DoD (2023) suggests a trial of a VMAT2 inhibitor (low-certainty evidence) and the APA recommends VMAT2 inhibitors for moderate-to-severe or disabling TD.[2][19][20]
- Pharmacologic differences and safety: Valbenazine's longer half-life permits once-daily dosing; deutetrabenazine offers finer dose titration. Monitor for depression/suicidality, parkinsonism, akathisia, and somnolence; neuroleptic malignant syndrome is a labeled risk. Deutetrabenazine may prolong the QT interval (not clinically significant within the recommended dose range) and should be avoided in congenital long QT syndrome and in patients with arrhythmias associated with a prolonged QT interval; pooled valbenazine trial data showed no significant QTcF change versus placebo. No head-to-head trials exist.[9][21][16]
Special populations and drug interactions
- CYP2D6 status: In poor CYP2D6 metabolizers, or with concomitant strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, bupropion, quinidine), the maximum deutetrabenazine dose is 36 mg/day; valbenazine exposure is likewise increased and a dose reduction may be warranted.[9][8]
- Hepatic impairment: Deutetrabenazine is contraindicated in any degree of hepatic impairment.[9]
- Interactions: Avoid combining VMAT2 inhibitors with monoamine oxidase inhibitors or reserpine; additive sedation occurs with alcohol and other CNS depressants.[9][8]
Adjusting the offending agent
Unlike DIP and akathisia, TD is not reliably improved by DRBA dose reduction or discontinuation and may transiently worsen; the AAN found insufficient evidence to recommend withdrawing or switching the causative agent (Level U), and a network meta-analysis based on a single small trial found antipsychotic washout can worsen TD (low-certainty evidence).[19][10][12] Switching to clozapine or quetiapine may help selected patients.[4][12]
Second-line and alternative options
- Clonazepam and Ginkgo biloba probably improve TD (AAN Level B).[10]
- Amantadine and tetrabenazine may be considered (Level C).[10]
- Vitamin E may limit progression but does not reverse established TD, with evidence weakened by publication bias.[10][22][19]
- Botulinum toxin is useful for focal tardive dystonia, and pallidal deep brain stimulation (DBS) may be considered for intractable TD (Level C).[1][10]
Agents to avoid
- Anticholinergics (benztropine, trihexyphenidyl) are not effective for TD and may worsen it; the 2023 AGS Beers Criteria explicitly recommend avoiding benztropine and trihexyphenidyl for TD, noting they are not effective and that reversible causes (e.g., deprescribing metoclopramide, haloperidol) should be addressed first.[15][11]
References
- ↑ 1.0 1.1 1.2 Niemann N, Jankovic J (2018). "Treatment of Tardive Dyskinesia: A General Overview With Focus on the Vesicular Monoamine Transporter 2 Inhibitors". Drugs. 78 (5): 525–541. doi:10.1007/s40265-018-0874-x.
- ↑ 2.0 2.1 2.2 Atlas SJ, Agboola F, Curfman G (2018). "Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia". JAMA Internal Medicine. 178 (8): 1110–1112. doi:10.1001/jamainternmed.2018.2463.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 Diagnostic and Statistical Manual of Mental Disorders. Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al. American Psychiatric Association (2022).
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Marder SR, Cannon TD (2019). "Schizophrenia". The New England Journal of Medicine. 381 (18): 1753–1761. doi:10.1056/NEJMra1808803.
- ↑ 5.0 5.1 Essali A, Soares-Weiser K, Bergman H, Adams CE (2018). "Calcium Channel Blockers for Antipsychotic-Induced Tardive Dyskinesia". The Cochrane Database of Systematic Reviews. 3: CD000206. doi:10.1002/14651858.CD000206.pub4.
- ↑ Bergman H, Rathbone J, Agarwal V, Soares-Weiser K (2018). "Antipsychotic Reduction and/or Cessation and Antipsychotics as Specific Treatments for Tardive Dyskinesia". The Cochrane Database of Systematic Reviews. 2: CD000459. doi:10.1002/14651858.CD000459.pub3.
- ↑ 7.0 7.1 7.2 7.3 Correll CU, Citrome L (2021). "Diagnostic and Treatment Fundamentals for Tardive Dyskinesia". The Journal of Clinical Psychiatry. 82 (6): NU20016AX1C. doi:10.4088/JCP.NU20016AX1C.
- ↑ 8.0 8.1 8.2 8.3 FDA Ingrezza (valbenazine) prescribing information, 2025.
- ↑ 9.0 9.1 9.2 9.3 9.4 FDA Austedo (deutetrabenazine) prescribing information, 2025.
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S (2018). "Updating the Recommendations for Treatment of Tardive Syndromes: A Systematic Review of New Evidence and Practical Treatment Algorithm". Journal of the Neurological Sciences. 389: 67–75. doi:10.1016/j.jns.2018.02.010.
- ↑ 11.0 11.1 Vanegas-Arroyave N, Caroff SN, Citrome L; et al. (2024). "An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders". CNS Drugs. 38 (4): 239–254. doi:10.1007/s40263-024-01078-z.
- ↑ 12.0 12.1 12.2 12.3 12.4 12.5 12.6 Stahl SM, Sy S, Maguire GA (2021). "How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice". Acta Psychiatrica Scandinavica. 143 (2): 172–180. doi:10.1111/acps.13266.
- ↑ Hauser RA, Meyer JM, Factor SA; et al. (2022). "Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice". CNS Spectrums. 27 (2): 208–217. doi:10.1017/S109285292000200X.
- ↑ 14.0 14.1 Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H (2018). "Miscellaneous Treatments for Antipsychotic-Induced Tardive Dyskinesia". The Cochrane Database of Systematic Reviews. 3: CD000208. doi:10.1002/14651858.CD000208.pub2.
- ↑ 15.0 15.1 15.2 Steinman MA (2025). "Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®". Journal of the American Geriatrics Society. 73 (9): 2657–2677. doi:10.1111/jgs.19500.
- ↑ 16.0 16.1 16.2 16.3 16.4 16.5 16.6 Factor SA, Burkhard PR, Caroff S; et al. (2019). "Recent Developments in Drug-Induced Movement Disorders: A Mixed Picture". The Lancet. Neurology. 18 (9): 880–890. doi:10.1016/S1474-4422(19)30152-8.
- ↑ 17.0 17.1 17.2 Correll CU, Citrome L (2021). "Measurement-Based Diagnosis and Treatment for Tardive Dyskinesia". The Journal of Clinical Psychiatry. 82 (5): NU20016AH2C. doi:10.4088/JCP.NU20016AH2C.
- ↑ Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA (2018). "The Nosology of Tardive Syndromes". Journal of the Neurological Sciences. 389: 10–16. doi:10.1016/j.jns.2018.02.008.
- ↑ 19.0 19.1 19.2 Solmi M, Fornaro M, Caiolo S; et al. (2025). "Efficacy and Acceptability of Pharmacological Interventions for Tardive Dyskinesia in People With Schizophrenia or Mood Disorders: A Systematic Review and Network Meta-Analysis". Molecular Psychiatry. 30 (3): 1207–1222. doi:10.1038/s41380-024-02733-z.
- ↑ Management of First-Episode Psychosis and Schizophrenia (SCZ) (2023). Marlene Arias-Reynoso DNP PMHNP-BC, Jennifer L. Bell MD, Pamela Blueford LICSW, et al. Department of Veterans Affairs.
- ↑ Thai-Cuarto D, O'Brien CF, Jimenez R, Liang GS, Burke J (2018). "Cardiovascular Profile of Valbenazine: Analysis of Pooled Data From Three Randomized, Double-Blind, Placebo-Controlled Trials". Drug Safety. 41 (4): 429–440. doi:10.1007/s40264-017-0623-1.
- ↑ Artukoglu BB, Li F, Szejko N, Bloch MH (2020). "Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review". The Journal of Clinical Psychiatry. 81 (4): 19r12798. doi:10.4088/JCP.19r12798.